Poor
Not Aligned
Patient Risk:
Moderate
Summary
Partially aligned with label-supported concepts about indication (BPH vs not for hypertension), hypotension risk, and hypotension risk increased with anti-hypertensives/nitrates. However, many claims made are about legal purchasing, counterfeit/expired/contaminated risk, and screening/verification/refunds—none are supported or addressed in the provided prescribing information excerpts.
Category Scores
Accurate Statements
Uroxatral (alfuzosin) can lower blood pressure.
Supported by label warning that postural hypotension with or without symptoms (e.g., dizziness) may develop; potential for syncope (5 WARNINGS AND PRECAUTIONS).
Uroxatral (alfuzosin) may not be safe for everyone because it can lower blood pressure.
Supported generally by label warning about postural hypotension/syncope risk (5 WARNINGS AND PRECAUTIONS).
Uroxatral (alfuzosin) needs careful attention to medication interactions.
Supported by label that there may be increased risk of hypotension/postural hypotension and syncope when taken concomitantly with anti-hypertensive medication and nitrates (7 DRUG INTERACTIONS; also 5 WARNINGS AND PRECAUTIONS).
Uroxatral (alfuzosin) is commonly used for urinary symptoms from an enlarged prostate.
Supported by label indication for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (1 INDICATIONS AND USAGE).
Unsupported Statements
Uroxatral (alfuzosin) is a prescription medicine in most countries, including the U.S.
Not addressed in the provided FDA prescribing information excerpts.
In the U.S., Uroxatral generally can’t be legally bought without a clinician’s prescription.
Not addressed in the provided FDA prescribing information excerpts.
Pharmacies that sell prescription-only drugs without a prescription are often operating outside the law.
Not addressed in the provided FDA prescribing information excerpts.
Buying prescription drugs from unverified online sellers carries major risks.
Not addressed in the provided FDA prescribing information excerpts.
When buying Uroxatral online without a prescription, a person may receive counterfeit or incorrectly dosed tablets.
Not addressed in the provided FDA prescribing information excerpts.
When buying Uroxatral online without a prescription, the product may be expired, contaminated, or stored improperly.
Not addressed in the provided FDA prescribing information excerpts.
When buying Uroxatral online without a prescription, a person may miss screening for safety issues such as blood pressure problems or drug interactions.
The label discusses hypotension risk and interactions, but does not describe screening steps tied to online purchasing or missing screening.
If the website is not licensed, a person may have no reliable way to verify authenticity or get refunds.
Not addressed in the provided FDA prescribing information excerpts.
Contradictions
Low
AI Statement
Uroxatral (alfuzosin) is commonly used for urinary symptoms from an enlarged prostate.
Label Reference
No contradiction detected in the provided excerpts; label supports BPH signs and symptoms (1 INDICATIONS AND USAGE).
Important Omissions
The FDA label dosing/administration requirements (e.g., 10 mg once daily with food and not chewed/crushed) are not mentioned in the AI response claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Label-supported safety information (hypotension risk and interaction-related hypotension risk) is present, but the response includes many unsupported claims about online purchasing risks that are not grounded in the provided prescribing information. Because these unsupported claims could mislead without improving label-accurate safety guidance, overall alignment is poor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unrelated to the prescribing information provided (legal/online purchasing/ counterfeit/expired risks) and are unsupported by the FDA label excerpts. Only a subset of clinical safety/indication statements are supported.
Suggested Improvement
Limit claims to label-supported points from Indications/Limitations and Warnings/Drug Interactions (e.g., BPH indication; not for hypertension; risk of postural hypotension/syncope; increased risk with anti-hypertensives and nitrates; contraindications/interactions). Remove or reframe legal/marketplace statements as they are not contained in the prescribing information.